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IZVLEČEK 
Namen dela: Sarkopenija pomembno vpliva na zaplete in preživetje bolnikov z jetrno cirozo. 
Zato bi bilo smiselno stopnjo sarkopenijo vključiti med MELD (lestvica za oceno jetrne 
odpovedi, ang. Model of end liver disease) kazalce s katerimi se razvršča bolnike na listo za 
presaditev jeter. Sarkopenijo lahko ugotovimo s pomočjo MR (magnetna resonanca, ang. 
Magnetic resonance) ali CT (računalniška tomografija, ang. Computed tomography) 
merjenjem volumna skeletne mišične mase v trebušni votlini. V raziskavi želimo ugotoviti ali je 
mogoče z ultrazvočno preiskavo premera mišice psoas in izračunom kliničnih kazalcev mišične 
mase oceniti sarkopenijo in vpliv sarkopenije na zaplete in preživetje pri bolnikih z jetrno cirozo. 
Cilji/hipoteze: Z ultrazvočno meritvijo premera mišice psoas pri bolnikih z  jetrno cirozo lahko 
ocenimo stopnjo  sarkopenije. Tako opredeljena sarkopenija je prognostični dejavnik za 
preživetje in za nastanek zapletov pri bolnikih z jetrno cirozo. 
Utemeljitev: Slaba prehranjenost in sarkopenija sta pomemben dejavnik za nastanek zapletov 
jetrne ciroze. Splošno stanje telesne prehranjenosti, še posebej sarkopenijo, je v vsakodnevni 
klinični praksi pri bolnikih z jetrno cirozo težko oceniti. Objektivno jo lahko ocenimo s CT ali 
MRI meritvami volumna oziroma ploščine skeletne mišične mase v trebušni votlini. Zaradi 
sevanja oziroma težje dostopnosti se v praksi CT ali MRI meritve mišične mase redko 
uporabljajo. Objektivna ocena sarkopenije s pomočjo ultrazvočne preiskave je enostavna in 
ponovljiva metoda, ki bi lahko ob dosedanji oceni MELD vplivala na razvrščanje bolnikov na 
listo za presaditev. Obenem bi lahko predstavljala napovedni dejavnik za zaplete jetrne ciroze, 
potrebo po hospitalizacijah in preživetje bolnikov z jetrno cirozo. 
Zasnova raziskave, opis metod in preiskovancev: Pri 75 zaporednih bolnikih z 
dekompenzirano jetrno cirozo, ki so opravili ultrazvočni pregled med januarjem 2016 in 
novembrom 2017 v naši bolnišnici, smo opravili retrospektivno analizo prospektivno zbranih 
podatkov. Dekompenzacijo jetrne ciroze smo pri bolnikih s potrjeno jetrno cirozo opredelili kot 
pojav ene ali več oblik dekompenzacije - pojav ascitesa, okužbe, hepatične encefalopatije, 
zlatenice ali varikozne krvavitve. Vse bolnike smo razvrstili po Child –Pughovi klasifikaciji. Pri 
vseh bolnikih smo ultrazvočno izmerili premer mišice psoas, določili preiskovančevo starost, 
spol, višino, telesno težo, indeks telesne mase in opredelili za raziskavo pomembne 
laboratorijske kazalce. Možnost uporabe ultrazvočne meritve mišice psoas smo preverili z 
odstotkom ponovljivosti zanesljive meritve premera mišice psoas in z oceno variabilnosti 
meritve. Premer mišice psoas smo pretvorili v ultrazvočni kazalec razmerja premera psoasa 
in telesne višine (ang. psoas-to-height-ratio; US-PTHR) in v kazalec psoas-mišica (ang. psoas-
muscle-index; US-PMI). Za oceno vpliva izračunanih ocen sarkopenije na pojav 
dekompenzacije in umrljivosti smo uporabili Coxovo analizo z upoštevanjem več faktorske 
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analize neodvisnih spremenljivk študijske skupine. Rezultate smo primerjali s skupino zdravih 
prostovoljcev.   
Rezultati. Ultrazvočna meritev premera mišice psoas je bila uspešna in zanesljiva pri vseh 
subjektih v kontrolni skupini in pri 54 (72%) od 75 vključenih bolnikov z dekompenzirano jetrno 
cirozo. Pri bolnikih je bila povprečna vrednost US-PTHR 20 mm/m (rang: 13-26; IQR 3 mm/m) 
in povprečna vrednost US-SMI 3.2 cm2/m2 (rang: 1.2-5.5, IQR 1.0 cm2/m2). V kontrolni skupini 
je bila povprečna vrednost US-PTHR 24 mm/m (rang: 20-28; IQR 2 mm/m) in povprečna 
vrednost US-SMI 4.5 cm2/m2 (rang: 3.2-6,0; IQR 0.8 cm2/m2). Mediana opazovanja bolnikov je 
znašala 11,7 mesecev. V tem obdobju je 37 (68.5%) bolnikov  potrebovalo hospitalizacijo 
zaradi ponovne dekompenzacije bolezni. 15 (27.8) bolnikov je umrlo, od tega 12 zaradi vzrokov 
povezanih z jetrno cirozo. US-PTHR je bil značilno povezan s hospitalizacijo (p<0.0001; HR 
0.717; 95% CI: 0.622- 0.828), kakor tudi US-SMI (p<0.0001, HR 0.881; 95% CI: 0.836-0.929). 
US-PTHR je bil značilno povezan s smrtnostjo (p=0.022; HR 0.825; 95% CI: 0.701-0.973), 
kakor tudi US-SMI (p=0.017; HR 0.930; 95% CI: 0.876-0.987). 
Zaključek. Ultrazvočna meritev mišice psoas je uporabna in zanesljiva pri približno 70% 
bolnikov z dekompenzirano jetrno cirozo. Ultrazvočno zasnovan izračun kazalcev skeletne 
mišične mase ima napovedno vrednost za pojav hospitalizacije in smrtnosti pri tej skupini 
bolnikov. Ultrazvočna meritev premera mišice psoas bi lahko predstavljala preprosto 
obposteljno metodo za stratifikacijo ogroženosti v tej populaciji. 
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ABSTRACT 
Background: Sarcopenia significantly affects the complications and survival of patients with 
liver cirrhosis. Therefore, it would be reasonable to include sarcopenia among MELD (Model 
of end liver disease) indices to better prioritize patients on the liver transplant waiting list. 
Sarcopenia can be detected by MRI (Magnetic resonance imaging) or CT (Computed 
tomography) measurements of the skeletal muscle area or volume in the abdominal cavity. 
This study aims to determine whether sarcopenia and its impact on complications and survival 
in patients with liver cirrhosis can be evaluated by ultrasound psoas muscle measurement and 
subsequent calculation of clinical muscle mass indices. 
Aims and hypotheses: Ultrasound measurement of psoas muscle diameter in patients with 
liver cirrhosis can assess the degree of sarcopenia. Thus defined sarcopenia is a prognostic 
factor for survival and complications in patients with liver cirrhosis. 
Rationale: Malnutrition and sarcopenia are important factors in the development of liver 
cirrhosis complications. The malnutrition, especially sarcopenia, is difficult to assess in 
everyday clinical practice in patients with liver cirrhosis. It can be objectively evaluated by CT 
or MRI measurements of the abdominal skeletal muscle volume or surface area. Because of 
iradiation or inaccessibility, such measurements are rarely used in clilnical practice. An 
objective assessment of sarcopenia by ultrasound is simple and reproducible method that 
could affect the classification of patients on the liver transplant waiting list. At the same time, it 
could represent a predictive model of liver cirrhosis complications such as the need for 
hospitalization and survival. 
Methods and study design: A retrospective analysis of prospectively collected data was 
performed in 75 consecutive patients with decompensated liver cirrhosis who underwent 
ultrasound examination between January 2016 and November 2017 at our hospital. Liver 
cirrhosis decompensation was defined in patients with confirmed liver cirrhosis as the 
occurrence of one or more types of decompensation - the occurrence of ascites, infection, 
hepatic encephalopathy, jaundice or varicose bleeding. All patients were classified according 
to the Child – Pugh classification. All patients underwent ultrasound measurements of the 
psoas muscle diameter. Simultaneously, we determined the patient's age, sex, height, weight, 
body mass index, and identified laboratory data important for the study. The applicability of 
ultrasond psoas measurement was verified. The psoas muscle diameter was converted into 
the ultrasound psoas-to-height-ratio index (US-PTHR) and into the ultrasound psoas-muscle-
index (US-PMI). Multifactorial Cox analysis was used to evaluate independent study group 
variables and to assess the impact of calculated sarcopenia estimates on the onset of 
decompensation and mortality,. The results were compared with those of the control group 
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consisted of healthy volunteers. 
Results. Ultrasound measurement of psoas muscle diameter was successful and reliable in 
all subjects in the control group and in 54 (72%) of the 75 enrolled patients with 
decompensated liver cirrhosis. In patients, the mean US-PTHR was 20 mm/m (range: 13-26; 
IQR 3 mm/m) and the mean US-SMI was 3.2 cm2/m2 (range: 1.2-5.5, IQR 1.0 cm2/m2). In the 
control group, the average US-PTHR value was 24 mm/m (range: 20-28; IQR 2 mm/m) and 
the average US-SMI value was 4.5 cm2/m2 (range: 3.2-6.0; IQR 0.8 cm2/m2). Restricted mean 
survival time was 11.7 months. During this period, 37 (68.5%) patients needed hospitalization 
due to further decompensation of the disease. 15 (27.8%) patients died, 12 of them due to liver 
cirrhosis related causes. US-PTHR was significantly associated with hospitalization (p <0.0001; 
HR 0.717; 95% CI: 0.622- 0.828) as well as US-SMI (p <0.0001; HR 0.881; 95% CI: 0.836-
0.929). US-PTHR was significantly associated with mortality (p = 0.022; HR 0.825; 95% CI: 
0.701-0.973) as well as US-SMI (p = 0.017; HR 0.930; 95% CI: 0.876-0.987). 
Conclusion. Ultrasound psoas muscle measurement is useful and reliable in approximately 
70% of patients with decompensated liver cirrhosis. The ultrasound-based calculation of 
skeletal muscle indices has a predictive value for the incidence of further hospitalization and 
mortality in this group of patients. Ultrasound measurement of psoas muscle diameter could 
represent a simple bedside method for risk stratification in this population. 
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1 INTRODUCTION 
1.1 Liver cirrhosis 
Liver cirrhosis is the final stage of advanced liver fibrosis that accompanies 
many chronic liver diseases. Etiologically, they have diverse clinical 
backgrounds (alcohol abuse, non-alcoholic steatohepatitis, chronic hepatitis B 
or C viral infection, immune-mediated diseases, etc.) that altogether lead to liver 
cell necrosis and secondary fibrogenesis due to prolonged inflammatory 
damage to liver tissue. The late consequence of liver tissue conversion to 
fibrous nodes is a decrease in liver function and the emergence of resistance to 
blood flow through the liver tissue (portal hypertension). According to the recent 
findings, the process of liver tissue decay and regeneration is a dynamic one, 
and often not irreversible; thus, the term advanced chronic liver disease (ACLD) 
is increasingly used in the medical literature instead of the term cirrhosis. Until 
the onset of disease decompensation, most chronic liver diseases occur in 
extremely latent form. Decompensation events are of particular importance for 
the clinical stages of the disease discernment which terminologically divides into 
the compensated (stages 1 and 2) and decompensated phase (stages 3-5; Fig. 
1). 
 
Figure 1. Stages of disease in ACLD (advanced chronic liver disease). Taken 
from Berzigotti A, Advances and challenges in cirrhosis and portal hypertension. BMC Med. 
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2017. Published with permission. CSPH - clinically significant portal hypertension; HE – 
hepatic encephalopathy; SBP – spontaneuos bacterial peritonitis; HRS – hepatorenal 
syndrome; GEV – gastroesophageal varices; EV – esophageal varices.  
Decompensated stage of the disease is highlighted by the appearance of non-
obstructive jaundice, variceal hemorrhages, frequent infections, hepatic 
encephalopathy, or the appearance of ascites. The stages of advanced chronic 
liver disease coincide well with the prognosis of patient mortality and thus 
represent the basis for clinical intervention or potential disease treatment (1-4). 
 
1.2 Liver cirrhosis and malnutrition 
Malnutrition is a common accompaniment to liver cirrhosis as it is present in 
approximately 20% of patients with compensated phase and in 60% of patients 
with decompensated phase of the disease (5). In a cirrothic patient, it has a 
markedly negative impact on the survival, quality of life and external stressors 
response (6). However, malnutrition in these patients is clinically commonly 
overlooked. Patients who begin to accumulate adipose tissue (sarcopenic 
obesity) or replace skeletal muscle fibers with fat cells (myosteatosis) are 
particularly difficult to evaluate (5,7). When treating a patient with ACLD, 
assesing the risk for developing malnutrition is an important part of dietary 
management. Screening is usually a one-time act to identify individuals with 
malnutrition or individuals at increased risk of malnutrition. The best known test 
for hospital use is the NRS 2002 screening test (NRS - Nutritional risk screening) 
developed by ESPEN (The European Society for Clinical Nutrition and 
Metabolism); and when appropriate, the use of RFH-NPT (Royal Free Hospital-
Nutritional Prioritizing Tool) is recommended (5,8). The NRS 2002 test is fast, 
reliable and repeatable (5). The initial screening involves 4 questions (Figure 2). 
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Initial screening I YES NO 
1. BMI under 20,5 
  
2. Body weight loss in the last 3 months? 
  
3. Diminished food intake in the last week? 
  
4. Severely ill patient (ICU,…)? 
  
Figure 2. NRS 2002 questionare. Published with permission. 
 
If one or more of the questions are answered as affirmative, the patient should 
be screened and evaluated for nutritional status. With this quick test, we can 
easily identify patients who are not at risk from those who are already at risk for 
malnutrition or who will become malnourished during hospitalization. The sooner 
we recognize patients at risk, the faster we can take action on case-based 
nutritional therapy with a team of different specialists: doctors, nurses, dietitians 
and pharmacists (5). 
Any wholesome approach to a patient with liver cirrhosis should then include an 
assessment of different body compartments composition with a focus on muscle 
mass, muscle function and patient’s frailty. The assessment of muscle mass is 
described in the following paragraphs, and the use of a Fried frailty index or 
Short Physical Performance Battery (SPPB) is recommended for the 
assessment of frailty (5-7). 
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1.3 Medical terms in nutrition management 
Malnutrition is a nutritional condition where the deficiency or imbalance of 
energy, protein or other nutrients causes adverse effects on the body's or 
tissue's composure, function and clinical outcome of the disease. Sarcopenia 
is a loss of muscle mass and a decrease in muscle strength and function. The 
loss is not solely due to muscular atrophy, but also involves the replacement of 
muscle with fat (myosteatosis) and connective tissue. Cachexia is a 
multifactorial syndrome that is defind as a severe loss of body weight, fat and 
skeletal muscle as a result of the accompanying disease; it is characterised by 
the increased protein breakdown and proinflammatory activity (8,9). More 
specifically, it is defined as losing at least 5% of body weight in 3-12 months or 
a decrease in BMI below 20 kg/m2 and concomitant presence of at least three 
out of the five additional criteria: reduced muscle strength, fatigue, anorexia, 
low lean body mass index (FFMI – Fat Free Mass Index) or pathological 
biochemical test results (CRP > 5 mg/L, Albumin < 32 g/L, Haemoglobin < 120 
g/L; 5). 
 
1.4 EASL and ESPEN guidelines for the management of nutrition in 
liver cirrhosis 
To better evaluate the nutritional status of patients with chronic liver disease, 
guidelines for the nutrition management were issued by the European 
Association for the Study of the Liver (EASL) in 2018 (3). The main parameters 
of nutritional risk include a decline in body mass index below 18.5 kg/m2 or the 
presence of advanced stage of decompensated liver disease (Child–Pugh C 
class). Proposed protocol for nutritional screening of patients with liver cirrhosis 
is shown in Figure 3 (10). 
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Figure3. Nutritional screening of a patient with liver cirrhosis. EASL Clinical Practice 
Guidelines on Nutrition in Chronic Liver Disease (2018; 3). BMI - body mass index. 
 
The 2019 ESPEN guidelines for the clinical nutrition in chronic liver disease also 
recommend screening for malnutrition in any patient with liver cirrhosis 
(Recommendation No. 3). They recommend the use of the RFH-NPT 
questionnaire (11) as a method of initial screening in this patient’s group. Both 
the ESPEN and EASL guidelines specifically emphasize the importance of early 
recognition of sarcopenia (10,11). 
 
1.5. Sarcopenia in liver cirrhosis 
Sarcopenia is often equated as a state of advanced malnutrition. Skeletal 
muscle accounts for two-thirds of body protein stores. Muscle mass reduction is 
directly responsible for reducing muscle strength and function. The condition is 
associated with complications such as poor mobility and quality of life and 
increased mortality (12). Muscle loss in sarcopenia is not solely at the expense 
of muscle atrophy, it also involves replacing muscle cells with fat and connective 
tissue. According to the report by Santilli et al. (12), it is recommended to classify 
sarcopenia into stages – prescarcopenia, sarcopenia and advanced sarcopenia. 
18 
 
Presarcopenia is characterized by the loss of muscle mass without concomitant 
loss of strength and functionality. This stage can only be defined by techniques 
that can measure muscle volume in a standardized manner compared to a 
healthy population. In addition to loss of muscle mass, sarcopenia is 
accompanied by loss of strength or function. As for advanced sarcopenia, it is 
characterized by the presence of all three signs (loss of muscle mass, strength 
and function). Protein supply in a sarcopenic patient is low due to chronic muscle 
degradation which is most clearly manifested during metabolic stress when 
muscle proteins should be mobilized very quickly to provide the body with amino 
acids for the liver, gut and immune system function. Sarcopenia is primarily a 
disease of the elderly, but its development may also be associated with various 
conditions of increased inflammatory activity (8). 
Sarcopenia in patients with liver cirrhosis is connected to age-related decline in 
muscle mass and to malnutrition. Studies show that malnutrition develops due 
to negative energy balance, loss of appetite, rapid satiety and poor food 
absorption. Concurrent illnesses or addictions (bacterial growth in the gut, 
pancreatic exocrine insufficiency, alcoholism) exacerbate the condition. 
Iatrogenic losses include ascites paracentesis and use of laxatives and 
diuretics. Frequent endoscopic imaging and laboratory examinations also affect 
diet and weight loss as well as sarcopenia (5,13,14). Therefore, liver cirrhosis is 
a state of accelerated starvation (5). In liver cirrhosis, cytokines that stimulate 
catabolic processes in the body are released. Due to the low glycogen stores, 
energy production is directed towards the breakdown of fatty acids. 
Gluconeogenesis is mainly pursued through amino acids breakdown, which 
worsens protein loss. Advancement of the state is also exacerbated by growth 
hormone and testosterone deficiency, decreased physical activity, and more 
frequent occurrence of hepatocellular carcinoma. Patients with liver cirrhosis are 
prone to replacing muscle fibers with fat cells (myosteatosis), which may further 
accelerate loss of muscle function and decline in muscle strength (14). In recent 
years, attention has been focused on the impact of sarcopenia and the 
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occurrence of decompensation events and mortality in patients with liver 
cirrhosis as well as on the importance of sarcopenia when assessing priority for 
liver transplantation. 
According to recent findings, sarcopenia has a significant influence on the 
occurrence of various forms of liver cirrhosis decompensation. Several studies 
have described that presence of sarcopenia increases the risk of covert or 
clinically detectable hepatic encephalopathy (15-17). According to the report by 
Nardelli S et al. (17) that summarizes latest important studies from this field, 
connection between hepatic encephalopathy and sarcopenia is in a form of a 
vicious cycle. Skeletal muscle, via glutamine synthase enzyme, is an important 
site for the breakdown of ammonia and glutamine, possibly involved in the 
occurrence of hepatic encephalopathy when impaired liver function is present. 
Skeletal muscle deficiency thus increases the content of these metabolites in 
the blood. Also, any catabolic stress increases the release of glutamine from 
skeletal muscle. On the other hand, ammonia is likely to be directly responsible 
for mitochondrial oxidative damage and autophagy of skeletal muscle cells; it 
also inhibits protein synthesis in skeletal muscle through stimulation of myostatin 
(17). Sarcopenia could significantly contribute to a reduced ability to perform 
more complex mental tasks through the occurrence of clinically covert hepatic 
encephalopathy (such as driving a car) and the occurrence of falls with 
consequent injuries, bleeding and fractures (17,18). There are no studies to 
demonstrate improvement in the mental status of the patient after the 
improvement of sarcopenia (17,18). 
There is no evidence of a direct dependence of portal hypertension on 
sarcopenia state. There is also no evidence that sarcopenia increases the risk 
of varicose bleeding in patients with liver cirrhosis. A monocentric study by 
Rodrigues SG et al. (19), comparing invasive measurement of hepatic vein 
pressure gradient (HVPG) and sarcopenia measured with CT scan, concluded 
that the degree and development of portal hypertension may be influenced by 
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indicators of adipose tissue preservation. The association with indicators of 
skeletal muscle conservation has not been confirmed. 
In the field of portal hypertension, important studies show the association 
between the refractory ascites and sarcopenia. Refractory ascites directly 
affects the patient's decreased appetite and physical fitness, thereby 
exacerbating the development of sarcopenia. Frequent punctures of albumin-
rich ascites probably further influence loss of protein from the body. Careful 
control of ascites volume by diuretic therapy should significantly contribute to 
slowing the development of sarcopenia in patients with liver cirrhosis (20). 
Aggressive feeding of sarcopenic patients in a study by Vidot H et al. (21) 
showed a reduced incidence of ascites and a reduced need for paracentesis in 
patients with decompensated liver cirrhosis. 
In an editorial for Liver International, Ebadi M and Montano-Loza AJ (22) 
critically evaluated studies that link sarcopenia with the infection’s occurrence in 
patients with liver cirrhosis. Studies have shown an interdependence between 
increased malnutrition in cirrhotic patients and the incidence of infections, and 
sarcopenia has been confirmed as an independent risk factor for infection and 
sepsis. After liver transplantation, more severe sarcopenia in the organ 
transplantation setting had a significant impact on the incidence of infections. It 
has also been reported that reduced muscle mass coincides with a poorer 
prognosis for patients with liver cirrhosis rated as Child A or B to the extent that 
the prognosis for infection coincides with patients in Child C class (23). 
 
1.5.2. Sarcopenia in liver cirrhosis - mortality and liver transplantation 
Given the aforementioned association of sarcopenia with decompensation of 
liver cirrhosis, it is not surprising that there is a strong relationship between 
sarcopenia state and mortality in this group of patients (24). Increased mortality 
of sarcopenic patients has also been demonstrated in patients with 
compensated cirrhosis who have experienced severe infection (23). In a large 
cohort of patients on the liver transplant waiting list, van Vugt et al. (25) 
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demonstrated that lower skeletal muscle mass was associated with increased 
mortality, especially in patients with low MELD priority (25). A study by Kim TY 
et al. (26) confirmed the existence of a link between sarcopenia and increased 
mortality in patients with ascites. Ishizu Y et al. (27) reported an increased 6-
week mortality in patients with sarcopenia after variceal bleeding. In this context, 
a new area of interest has emerged in recent years regarding the possible place 
of sarcopenia among indices that determine the assessment of patients' priority 
on the liver transplant waiting list when calculating the MELD score. Experts 
agree that sarcopenia is an area requiring targeted treatment in a group of 
patients on the liver transplant waiting list (28-30). Opinions are divided 
regarding the formation of a specific S-MELD score (Sarcopenia-MELD), with 
opinions that there is no specific evidence of the usefulness of such priority 
(25,28) and opinions that are strongly in favor of such score (29,30). Study 
differences in performances between MELD and S-MELD can be partly 
explained by the weight ratio added to sarcopenia in the computational process 
(25). In the absence of official guidelines, this field will certainly require a more 
detailed study meta-analysis and expert agreement in the future. 
 
1.6 Sarcopenia assessment 
1.6.1 Standard tests 
According to the guidelines, a combination of muscle mass assessment with 
Dual-energy X-ray absorptiometry and muscle function evaluation by 
measurement of gait speed (e.g. 4m walk gait speed test) may be used to 
evaluate sarcopenia. In case of inability to perform the walk test, it is 
recommended to perform hand grip strength test (8).  
In basic diagnostics, anthropometric methods are most commonly used (e.g. 
patient weight and body mass index (BMI), lean body weight, triceps skin fold 
caliper, mid arm and thigh circumference, phase angle). In order to further 
evaluate the distribution of individual body comparments, we then use more 
complex measurements, such as Bioelectrical impedance analysis (BIA) and 
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Dual-energy X-ray absorptiometry. Most commonly determined laboratory 
values are albumin, iron, zinc, prealbumin, transthyretin and phosphate. 
Follistatin (myokin) and myostatin are used as useful laboratory parameters in 
studies, and various laboratory indices of malnutrition assessment are 
proposed. These investigational methods have an adequate predictive value in 
the evaluation of sarcopenia associated with inflammatory processes but are 
less useful in the detection of sarcopenia in patients with decompensated liver 
cirrhosis (Figure 3). This group of patients have frequent occurrence of 
sarcopenic obesity and complex distribution of extracellular fluid due to ascites 
and peripheral edema. Both conditions significantly affect the objectivity and 
reproducibility of both basic and advanced anthropometric investigative 
methods (8-11). 
 
1.6.2 Imaging tests 
i) Conventional imaging techniques 
In recent years, clinical research has focused on finding direct indices of muscle 
mass preservation in patients with liver cirrhosis. Measurements of the 
abdominal muscle mass area allow a good estimate of the body skeletal muscle 
mass volume. The most commonly measured muscles are the psoas muscle 
and the erector spinae muscle or derived indices – PMI (Psoas muscle index), 
PTHR (Psoas muscle to height ratio), PMA (Psoas muscle area) and SMI 
(sceletal muscle index; 31-36). According to EASL guidelines, imaging with CT 
or MRI performed as part of hepatocelular carcinoma screening can be used to 
evaluate sarcopenia (10). As a gold standard, it is recommended to measure 
the area of the entire skeletal muscle mass at the level of the third lumbar 
vertebra (10). These tests are often associated with decreased availability, 
contrast agent use, higher costs and patient irradiation. Also, the specific cut-off 
values have not yet been validated and have been used from oncology 
population studies (10). CT and MRI examination are very accurate and precise 
in the assessment of sarcopenia, but in vast majority of cases require a specially 
trained radiologist. The captured image is static, but on the other hand 
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independent of the patient's constitution. Due to some limitations (iradiation, 
etc.), both investigations are not feasible in all patients (Figure 4). 
 
 
Figure 4. Assessment of body composition with different investigation methods 
in a patient with liver cirrhosis (33). BIA - Bioelectric impedance analysis; MAC – mid 
arm circumference; MAMC - mid-arm muscle circumference; WC - waist circumference; W:H 
- Waist-to-hip ratio; CSA - cross-sectional area. 
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Figure 5. Symbolic representation of CT and ultrasound muscle mass 
assessment. 
 
ii) Ultrasound examination 
According to Tandon et al.'s analysis, ultrasound evaluation of skeletal muscle 
mass has the potential to evaluate muscle diameter, surface area, echogenicity 
and tissue integrity. The accuracy and precision of the method is moderate to 
high (Figure 4). It probably requires a trained investigator, but the technique of 
the investigative method is not particularly challenging to learn. The priority is 
given to the accessibility and repeatability of the ultrasound examination. The 
investigation shows a relatively high dependence on the patient's constitution, 
and there are no current definitions or cut-off values for liver cirrhosis (33). 
Tandon et al. (33) have proposed a model for ultrasound sarcopenia 
assessment by combining the thigh muscle diameter measurement with the 
body mass index. The model shows moderate accuracy compared to CT 
measurements of the psoas muscle, but without clinical relevance comparison 
to different stages of liver disease (37). The ultrasound method of measuring 
the diameter and surface area of the psoas muscle was presented with two 
Japanese studies in healthy subjects and in a group of patients with liver 
cirrhosis (38,39). The analysis showed good correlation with CT measurements 
of psoas muscle. Both studies did not compare their results with clinical 
endpoints of sarcopenia. There is no data regarding the possible use of 
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ultrasound for sarcopenia evaluation in the European population of patients with 
liver cirrhosis. 
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2 OBJECTIVES AND HYPOTHESES 
 
 
2.1 Purpose 
Proposal of the study is to determine whether sarcopenia assessment in 
patients with liver cirrhosis can be reliably done by ultrasound measurements of 
the psoas muscle. Expected confirmation of the hypothesis would facilitate the 
detection and early treatment of sarcopenia in patients with decompensated 
liver cirrhosis. 
 
 
2.2 Hypotheses 
Ultrasound measurement of psoas muscle diameter in patients with liver 
cirrhosis can assess the degree of sarcopenia. 
Thus defined sarcopenia is a prognostic factor for survival and complications in 
patients with liver cirrhosis. 
 
 
2.3 Objectives of the work 
The objectives of the work will be achieved: 
- by ultrasound measurement of the psoas muscle diameter and subsequent 
calculation of clinical indices, 
- by analyzing clinical data on mortality and the need for further hospitalization 
due to decompensation of liver cirrhosis in the study group, and 
- by comparing this type of sarcopenia assessment in the study and control 
group. 
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3 MATERIALS AND METHODS 
Retrospective analysis of prospectively collected results was obtained with the 
approval of the National Medical Ethics Committee, Republic of Slovenia (No. 
0120-448/2018/9). 
3.1. Description of the subjects 
Between January 2016 and November 2017, a total of 75 patients were 
consecutively enrolled for an observational study. Patients with previous or 
existing decompensation of liver cirrhosis were included in the study. Patients 
were selected from the waiting list for an ultrasound (US) examination in the 
General Hospital Celje, Department of Gastrointestinal Diseases; a population 
of patients with liver cirrhosis and ultrasound screening for hepatocellular 
carcinoma (HCC). 
Inclusion factors were: presence of cirrhosis according to clinical and 
radiological criteria (US or CT morphological signs of liver cirrhosis, reliable 
elastographic value of > 12kPa, laboratory signs of impaired liver function 
according to the CHILD score); presence of ongoing or previous 
decompensation defined as ascites, varicose bleeding, hepatic encephalopathy, 
jaundice or severe bacterial infection (requiring hospital treatment) within one 
year before being included in the study. The presence of ascites was confirmed 
in all cases by ultrasound. Ascites should have been a transudate (SAAG > 11 
g/L). The existence of hepatic encephalopathy or jaundice was defined 
according to the EASL guidelines (40,41). Extrahepatic cause of jaundice was 
excluded with US in all cases. Varicose haemorrhage was confirmed by 
gastroscopy. Signs of infection requiring hospitalization were defined as an 
acute increase of inflammatory blood indicators (CRP, procalcitonin) and the 
need for antibiotic treatment. We did not include patients with known HCC or 
any other active cancer; otherwise, there was no exclusion criteria. 
As a control group, we included 20 healthy subjects with no known chronic 
internal organ disease and no active cancer. Patients were again selected from 
the patients waiting list requiring an ultrasound examination at our department 
28 
 
in our hospital. If they agreed to participate in the study, they should not have a 
known chronic liver disease, nor should they have morphologic signs of 
advanced liver fibrosis or clinically relevant liver steatosis. The latter was 
determined by comparing the echogenicity of the liver parenchyma with respect 
to the adjacent kidney parenchyma. 
Clinical data relevant to the study – gender, age, height, weight, etiology of 
chronic liver disease – and the occurrence of prior or existing cirrhosis 
decompensation were separately collected from the electronic computer system 
(Birpis) at our hospital. Data from standard laboratory tests (hemogram, 
electrolytes) and tests relevant for the determination of liver and kidney function 
were also collected. Blood sampling was performed within a regular outpatient 
examination performed 1 to 3 months before the ultrasound examination. In the 
control group, the following clinical data were collected from the electronic 
system: gender, age, height, weight and body mass index. 
 
3.2. Ultrasound psoas muscle measurement 
The ultrasound examination was performed by a doctoral student with acquired 
knowledge of ultrasound examination that surpassed the required learning 
curve for an independent examination. As an investigator, I was not aware of 
the laboratory characteristics of the subject. The patient was fasting for 6 hours 
and lying in a supine position. The ultrasound examination was performed with 
an Esaote MyLab EightTM apparatus (Genoa, Italy; Figure 6) and using a mono-
crystal convex abdominal probe (range of 1-8 MHz). The examination was 
performed at the ultrasound clinic, General Hospital Celje, Department of 
Gastrointestinal Diseases. 
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Figure 6: Ultrasound apparatus used in our study (Easote, Genoa, Italy; shown 
with permission). 
 
During the examination, the right psoas muscle, its anterior and posterior 
margins, and the lumbar vertebra adjacent to it, were precisely identified in each 
patient in both study and control group. Abdominal probe was placed in the 
sagittal plane at subphrenal right location, just above the upper anatomical 
border of the pelvis (iliac crest). By moving the ultrasound probe anteromedially 
and posterolaterally, the largest ultrasonically visible psoas muscle diameter 
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was defined (Figure 7-11).
 
Figure 7: Anatomical boundaries in the abdominal cavity. A - kidney, B - inferior 
vena cava, C - aorta, D - psoas muscle, E - sacrum, F - ureter, G – iliac crest. 
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Figure 8: Sketch of organs relationship during the ultrasound measurement. 
Anatomical borders: A - lower edge of the right kidney, B - anterior and posterior 
edge of the psoas muscle, C - iliac crest, D - anterior margin of lumbar vertebrae. 
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Figure 9: Measurement of the psoas muscle in a healthy subject. A - 
subcutaneous fat, C - edges of muscle psoas. E - position of the iliac crest, F - 
position of the right kidney. 
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Figure 10: Measurement of the psoas muscle in a patient with liver cirrhosis. A 
- subcutaneous fat, B - intestine, C - edges of the psoas muscle, D - lumbar 
vertebrae, E - position of the iliac crest, F - position of the right kidney. 
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Figure 11: Determining the maximum psoas diameter in a patient with liver 
cirrhosis. A - The edges of the psoas muscle. 
 
 
As a doctoral student, I performed every measurement of the maximum psoas 
diameter as a triplicate in millimeters (mm). The calculated mean of all three 
measurements in millimeters (mm) was rounded to the nearest tenth of the unit 
and then used as the final result. 
For the purpose of the study, we defined the term reliable measurement of the 
psoas muscle. The “reliable” measurement had to meet the following criteria: 
a) all the anatomical borders clearly indentified during the measurement (Figure 
6); b) maximum psoas diameter between each of the three measurements did 
not deviate from the remaining two by more than 5 mm. Measurements that did 
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not meet these criteria were considered unreliable and excluded from the final 
analysis. Factors that influenced the unreliable measurements were identified 
separately. 
In analogy to what is proposed for CT-based psoas-derived indices, we 
calculated the Ultrasound psoas-to-height-ratio (US-PTHR) as a quotient of the 
average psoas diameter and patient’s height (unit mm/m) and Ultrasound psoas 
muscle index (US-PMI) according to the following formula: US-PMI = Π x psoas 
radius2/ pateint’s height2 (unit cm2/m2). 
 
3.3 Statistical analysis 
We rounded the US-PTHR values to the closer entire unit of the calculated value 
and US-PMI values to the closer unit with one decimal. The demographic and 
clinical data of the study population, laboratory data and ultrasound 
measurement data were anonymized and entered into an electronic database 
for further statistical analysis. Descriptive summary statistics of the population 
were performed. Summary values were described as the average ± standard 
deviation (SD) and/or as a median, range and interquartile range (IQR) when 
appropriate (according to the distribution of the processed data). Comparisons 
between patients and healthy controls were done using T-test and Chi-square 
as appropriate. Univariate and multivariate analyses were performed using Cox 
model and logistic regression. In order to evaluate the correlation between 
numerical variables, a multi-linear regression analysis was performed. The 
statistical analysis was carried out with the SPSS 22.0 package (SPSS Inc., 
Chicago, IL USA). The alpha value was set at 0.05. All p-values were two-sided. 
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4 RESULTS 
Main clinical characteristics of the study and control group are given in Table 1 
(descriptive statistics). 
 
4.1. Applicability of ultrasound for psoas muscle measurement in 
patients with decompensated cirrhosis 
 
Ultrasound measurement of the psoas muscle diameter was successful and 
reliable in 54 (72%) out of 75 included patients. In the remaining 21 patients, the 
measurement was of poor quality (unreliable) in 7 (9.3%) and not at all possible 
in 14 (18.7%) patients. The acquisition of any measurement was thus estimated 
to be possible in approximately 80% of the study population. Measurement was 
less reliable in patients with very high or very low abdominal circumference. As 
expected, interposition of abdominal gas from the surrounding structures was 
observed. In addition, the measurement was slightly influenced by the 
investigator’s experience, since a slight increase in frequency of successfully 
obtained measurements was reported at the later stage of the study. Other 
contributing factors affecting the measurement were the presence of ascites 
(more reliable measurement in patients without ascites) and the general state 
of the patient (difficulties to lay still on the back). The average measurement 
took place in 5 to 10 minutes. 
In reliable measurements, the average psoas diameter was 34 mm (range: 20–
46; SD 5; IQR 5 mm). The estimated relative error of ultrasonic measurement 
was 0.08 (8%) (absolute measurement error 3 mm). As expected, the obtained 
values varied greately among subjects. Therefore, all values were indexed to 
patients’ height (US-PTHR and US-PMI) for further analysis (Table 2). The 
average US-PTHR value was 20 mm/m (range: 13–26; IQR 3 mm/m) and the 
average US-PMI was 3.2 cm2/m2 (range: 1.2–5.5, IQR 1.0 cm2/m2). 
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Table 1 - Main clinical characteristics of the included patients 
Variable Study group 
(n=54) 
Control group 
(n=20) 
Age, yrs 63 ± 11 57  ± 15 
Males, n (%) 39 (72%) 14 (70%) 
BMI, kg/m2 (range) 28.1 ± 5.3 27.8  ± 3.5 
BMI obese, n (%) 16 (32%) 
 
Cirrhosis etiology (alcohol/NAFL-NASH/other), n 
(%) 
36/8/10 
(67/15/18%) 
 
Ascites, n (%) 42 (78%) 
 
Encephalopathy, n (%) 15 (28%) 
 
Varices, n (%) 35 (71%) 
 
Creatinine (μmol/L) 86  ± 32 
 
Bilirubin (μmol/L) 64  ± 112 
 
AST (μU/L) 1.1  ± 0.8 
 
ALT (μU/L) 0.8  ± 0.6 
 
Albumin (g/L) 34  ± 8 
 
INR 1.4  ± 0.3 
 
Platelet count (n*109/mm3) 131  ± 71 
 
Na-MELD score 15  ± 7 
 
CHILD score 8  ± 2 
 
Developed HCC in the follow up, n (%) 7 (13%) 
 
Cause of hospitalization in the follow-up 
(infection/ascites/HE/other), n (%) 
9/14/8/5 
(25/39/22/14%) 
 
Cause of death (infection/HCC/other), n (%) 5/6/4 (33/40/27%) 
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Table 2 - Psoas diameter, US-PTHR and US-PMI data of the included 
patients. The p value refers to the comparison of patients with cirrhosis and controls. 
 
Variable Patients with cirrhosis 
(n=54) 
Control group 
(n=20) 
p 
Psoas diameter 
(mm) 
Median 
Min-Max 
IQR 
 
34 
20-46 
5 
 
41 
32-48 
7 
p < 
0.0001 
US-PTHR (mm/m) 
Median 
Min-Max 
IQR 
 
20 
13-26 
3 
 
24 
20-28 
2 
p < 
0.0001 
US-PMI (mm2/cm2) 
Median 
Min-Max 
IQR 
 
3.2 
1.2-5.5 
0.9 
 
4.5 
3.1-6.0 
0.8 
p < 
0.0001 
 
 
 
 
 
 
 
 
 
39 
 
4.2. Applicability of ultrasound for psoas muscle measurement in 
control subjects 
 
In the control group, ultrasound measurement of the psoas muscle diameter 
was successful and reliable in 20 out of 20 included subjects (100%). The 
average psoas diameter was 41 mm (range: 32–48; IQR 7 mm). The average 
US-PTHR value was 24 mm/m (range: 20–28; IQR 2 mm/m). The average US-
PMI was 4.5 cm2/m2 (range: 3.2–6.0; IQR 0.8 cm2/m2). US-PTHR and US-PMI 
were significantly higher in control subjects vs. patients (p < 0.0001 in both 
cases, confirmed after adjustment for age and gender). 
 
4.3. Ultrasound-based psoas muscle indices and hospitalization due 
to further cirrhosis decompensation 
 
The median follow-up was 12 months. Over the follow-up, 37 patients (68.5%) 
needed hospitalization due to further cirrhosis decompensation (9 due to 
infection, 14 due to clinically relevant ascites and 8 due to hepatic 
encephalopathy; in some instances these were associated with variceal 
bleeding, alcoholic hepatitis and acute kidney injury). Both US-PTHR and US-
PMI were associated with risk of hospitalization due to further decompensation 
of cirrhosis with an odds ratio of 0.16; (95% CI 0.05–0.50; p = 0.002) and 0.58 
(95% I 0.42–0.81; p = 0.002), respectively. The result confirms that a higher 
muscle mass assessed by ultrasound is associated with lower hospitalization 
due to further cirrhosis decompensation of any type. After adjusting for gender, 
the results did not change. Figure 12 shows the probability of hospitalization due 
to further cirrhosis decompensation according to an US-PTHR above or below 
the median value in the present series. As shown, the actuarial risk of 
hospitalization at 12 months was about 65% in patients with US-PTHR below 
the median and only 10% in patients with US-PTHR above the median (Figure 
12). On multivariate analysis adjusted for MELD, CHILD and presence of 
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varices, either US-PTHR (HR 0.717; 95% CI 0.622–0.828; p < 0.0001) or US-
PMI (HR 0.881, 95% CI 0.836–0.929; p < 0.0001) remained independently 
associated with hospitalization due to further cirrhosis decompensation. 
 
 
Figure 12. Probability of hospitalization due to further decompensation of 
cirrhosis according to US-PTHR above or below the median in the study 
population. The grey areas indicate the 95% CI. PTHR — psoas to height ratio. 
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4.4. Ultrasound-based psoas muscle indices and mortality in 
cirrhosis 
 
Over the follow-up, 15 patients died (27.8%). Median survival time was 14.0 
months (95% CI 5.3–10.7) and restricted mean survival time was 21.1 months 
(95% CI 9.3–14.0). In 12 patients, the cause of death was liver related (bacterial 
infection in 5; HCC in 6; variceal bleeding in 1); 2 patients died for sudden 
cardiac arrest; and in one case the cause of the death could not be established. 
On multivariate analysis adjusted for MELD score, US-PTHR was related to 
mortality (p = 0.022; HR 0.825, 95% CI 0.701–0.973), as was US-PMI (p = 
0.017; HR 0.930, 95% CI 0.876–0.987) being the likelihood of mortality lower as 
US-PTHR (or US-PMI) increase (Figure 13). 
 
 
Figure 13. Probability of survival according to US-PTHR above or below the 
median in the study population. The grey areas indicate the 95% CI. PTHR — 
psoas to height ratio. 
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5 DISCUSSION 
 
In a retrospective analysis of prospectively collected data at one secondary 
hospital center, we confirmed that ultrasound measurement of psoas muscle 
diameter and derived sarcopenia indices are applicable in patients with 
decompensated liver cirrhosis and show clinically relevant significance, as they 
are associated with prospects for further decompensation of the disease 
requiring hospitalization and with mortality in this population. 
Our study indicates about 80% success of the acquisition of any measurement 
and 72% success rate in obtaining a reliable measurement. The percentages 
are lower compared to the control group of subjects without liver disease where 
the measurement success was 100%. Our results are comparable to the results 
of Japanese studies in terms of measurement performance in healthy volunteers 
(38, 39). However, the applicability of our method in patients with liver cirrhosis 
is significantly lower than that reported by Kobajashi et al. (39; 100% 
applicability of psoas measurement at the right groin area). We believe that the 
difference in outcome is partly explained by the different investigation protocol 
(measurement site: right suphrenal in our study and right groin in the Japanese 
study) and partly with the different body habitus in the asiatic and caucasian 
populations. Since the visualization of the psoas at the groin area was in our 
previous experiences often blurred in decompensated cirrhosis due to ascites 
or intestinal air interposition, the measurement site mentioned in our study was 
chosen based on the experience of the pilot tests. The reliable image 
representation in our study was also significantly influenced by the waist 
circumference. In this sense, CT-derived measurement of psoas muscle 
diameter has an important advantage, since the image is captured statically and 
easily measured by a physician who has no experience in performing an 
examination (33-35), and can be done irrespective of waist circumference or 
decompensated state of disease. Due to the position of the muscle, the maximal 
diameter of the psoas muscle is also easier and more accurately measured by 
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CT scan (the direction of the largest diameter lies posterolateral - anteromedial 
in the sagittal plane). Additionally, the psoas derived parameters alone may not 
be as accurate as when considering all the muscle area at specific lumbar level, 
which according to accepted guideliness should represent the golden standard 
to assess sarcopenia (10). On the other hand, we observed in our study that, in 
the case of clearly identifiable anatomical boundaries and in the hands of an 
experienced investigator, the determination of the maximum muscle diameter 
had a low variability. 
Ascites limited the ultrasound visibility of the psoas muscle, which can be a 
significant impediment to the introduction of the proposed method into everyday 
practice. As a possible solution, we suggest a measurement immediately after 
the ascites puncture has been performed. An important limitation of our study is 
the lack of comparison with the CT measurement of psoas muscle diameter, 
which would require a separate study design. 
Given that non-alcoholic steatohepatitis is becoming the most important etiology 
of cirrhosis in the Western world population, the reduced chance of having a 
reliable ultrasound psoas muscle measurement in a patient with increased waist 
circumference may represent a significant obstacle in this group of patients. In 
this case, it would probably be easier to use the sarcopenia estimation model 
proposed by Tandon et al. (38) in the clinical practice instead (ultrasound 
evaluation of thigh muscle thickness and concurrent body mass index analysis). 
Despite these limitations, we have been able to demonstrate in our population 
of patients that ultrasonically assessed US-PTHR and US-SMI indices are 
associated with risk for further decompensation requiring hospitalization. Unlike 
other studies in the field that have used CT scans to evaluate sarcopenia, we 
have not been able to demonstrate a gender specific difference in this field (25-
35). This is probably due to the low prevalence of women in our population, 
which is expected given the epidemiology of liver disease in Slovenia (most 
often the result of harmful alcohol drinking, which is more common in men). We 
also failed to demonstrate that sarcopenia is a risk factor for early re-
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hospitalization (within 3 months), as reported by studies in the liver transplant 
candidate group (35,36). We believe that sarcopenia is likely to be higher in the 
group of patients awaiting liver transplantation, which may have an effect on 
higher risk for early decompensation and mortality. 
It has been demonstrated that CT assessed psoas indices independently predict 
mortality in patients with decompensated liver cirrhosis. In our study, we 
confirmed that ultrasonically assessed psoas muscle indicators also 
independently predict mortality in patients with decompensated liver cirrhosis 
(31,32,35,36). According to Montano-Loza (5), sarcopenia could be an 
important determinant of the clinical decision-making regarding liver 
transplantation, with results showing a possible beneficiary effect in a subgroup 
of patients with severe sarcopenia. Van Vugt et al. (24) thus observed that 
sarcopenia was an important cause of mortality, especially in patients with 
relatively low MELD score. Validation of the Sarcopenia-MELD score over a 
larger cohort of patients was performed but failed to demonstrate that inclusion 
of sarcopenia in the MELD score adds significant value in predicting mortality in 
patients on the liver transplant waiting list. The need for more extensive 
validation of the aforementioned score is foreseen for a more accurate 
assessment of its prognostic value (24). In this area, ultrasound examination 
methods could have a significant advantage since they are simple and bedside 
methods which would probably facilitate the accessibility of clinical stratification 
of patients with decompensated disease. However, since ours is a proposed 
method that has not been studied in the population of patients awaiting liver 
transplantation, and because our study did not propose limit values for 
ultrasound indices when defining sarcopenia, at this time it could only provide 
the basis for additional studies which would more precisely define its usefulness 
in this field. 
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5.1 Limitations of our study 
While interpreting the results, we need to be aware of some limitations of our 
research. First, it is a retrospective and monocentric data analysis involving a 
relatively small number of patients. In addition, an ultrasound examination was 
performed by a single, highly trained investigator, which does not allow us to 
analyze information on the inter-observer reproducibility of the examination. Our 
study also fails to compare its results with the CT scan which is currently 
proposed as the standard investigative method (10), nor did we consider many 
other factors that significantly affect the clinical outcome of sarcopenia in the 
group of patients with decompensated cirrhosis (e.g., the impact of muscle 
function, the influence of fat and connective tissue remodeling of skeletal 
muscle). According to some authors, adipopenia (loss of visceral and 
subcutaneous fat) has an important prognostic role in the female sex which 
cannot be estimated by our ultrasound method (14). As a gold standard for 
sarcopenia assessment, it is also suggested to estimate the whole skeletal 
mussle surface area at the L3 vertebra level (10), which due to its limitations, 
ultrasound cannot provide. In terms of quality and affordability, the ultrasound 
machine in our investigation belongs to the mid-price and higher quality class. 
Given the necessary characteristics of the measurement suggested in our study, 
we believe that the measurement can be performed with any newer ultrasound 
device using monocrystalline abdominal probes. However, the use of older 
appliances can significantly affect the transparency and thus the measured 
muscle diameter. 
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5.2 Clinical applicability of the proposed ultrasound indices 
Despite some limitations, the results of our study indicate the utility and 
feasibility of simple, accessible, objective, reproducible and bedside method 
when measuring psoas diameter as a sarcopenia indicator in patients with 
decompensated liver cirrhosis. Ultrasound psoas muscle measurement has 
prognostic value in terms of mortality and clinical prognosis for the course of the 
disease in terms of decompensation. 
We believe that routine use of the proposed method during ultrasound 
examination of a patient with decompensated cirrhosis could allow early 
detection and monitoring of sarcopenia. 
In our study, we demonstrated an association between sarcopenia and 
increased patient mortality. In the field of liver transplantation, MELD score is 
the commonly used predictor for cirrhosis related mortality and as such an 
established method for assigning patients to a liver transplant waiting list. In this 
sense, our study indirectly supports the proposed inclusion of sarcopenia in 
clinical stratification (e.g. in the form of Sarcopenia-MELD), thereby influencing 
the possible future stratification of patients on the transplant waiting list with S-
MELD score. 
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6. CONCLUSIONS 
Ultrasonic measurement of psoas diameter is feasible in a population of patients 
with decompensated liver cirrhosis. 
When comparing the median of patients with liver cirrhosis and the group of 
healthy volunteers, the psoas diameter measured by the proposed ultrasound 
method is significantly different (smaller). 
The calculated ultrasound indices (US-PTHR, US-PMI) show adequate clinical 
properties for indirect risk assessment regarding the development of further 
decompensation of liver cirrhosis and mortality. 
Ultrasound sarcopenia assessment using psoas diameter and US-PTHR/US-
PMI indices can represent a useful bedside clinical tool for identifying and 
monitoring sarcopenia in a patient with liver cirrhosis. 
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7 ORIGINAL CONTRIBUTION TO KNOWLEDGE 
This is the first description of sarcopenia assessment with an ultrasound method 
and the first to use a psoas muscle measurement (novel type of measurement 
technique, first in a group of patients with liver cirrhosis) on a global scale. It is 
also the first description of any ultrasound assessment of sarcopenia using a 
psoas muscle measurement as an indicator in the accessible literature in the 
Western population. 
The validated hypotheses provide a simplified assessment of sarcopenia with 
the proposed model of our study which could significantly facilitate and improve 
the treatment of sarcopenia in patients with liver cirrhosis. Because of their 
prognostic value, these indicators would also be appropriate for assessing 
probability of further decompensation and mortality in this group, thereby 
influencing the prioritization of patients that are candidates for liver 
transplantation. 
 
8 POSSIBLE RESEARCH AREAS BASED ON ULTRASONIC 
ASSESSMENT OF SARCOPENIA 
 
Based on our research, new areas in which our knowledge and experience 
could be upgraded are being opened-up: 
- cut-off values proposal for the before mentioned ultrasonic indices when 
defining sarcopenia in patients with liver cirrhosis, 
- sarcopenia impact on the onset and progression of portal hypertension in 
patients with liver cirrhosis, 
- comparison of our ultrasound measurements with measurements taken by 
conventional radiological methods (CT, MRI), 
- sarcopenia impact on muscle function loss in patients with liver cirrhosis and 
their quality of life. 
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9. RAZŠIRJEN POVZETEK DISPOZICIJE V SLOVENSKEM JEZIKU 
 
9.1 Uvod 
Jetrna ciroza je končna faza napredovanja jetrne fibroze, ki spremlja številne 
kronične bolezni jeter. Etiološko gre za raznoliko klinična ozadja (zloraba 
alkohola, nealkoholni steatohepatitis, kronična okužba z virusom hepatitisa B ali 
C, imunsko pogojene bolezni,…), ki zaradi dolgotrajne vnetne poškodbe 
jetrnega tkiva vodijo v propad jetrnih celic in fibrogenezo. Posledica napredovale 
pretvorbe jetrnega tkiva v fibrozne vozliče je upad jetrne funkcije in pojav upora 
proti pretoku krvi skozi jetrno tkivo (portalna hipertenzija). Dinamičen proces 
propadanja in obnove jetrnega tkiva glede na zadnja spoznanja velikokrat ni 
nepovraten, zato v medicinski literaturi namesto izraza ciroza čedalje pogosteje 
uporabljamo izraz napredovala kronična bolezen jeter (ACLD). Večina kroničnih 
jetrnih bolezni poteka v izrazito nemi obliki vse do pojava dekompenzacij bolezni. 
Slednje so izrazito pomembne za klinično delitev bolezni, ki se tako 
terminološko deli v kompenzirano (stadij 1 in 2) in dekompenzirano fazo (stadij 
3-5; slika 1). Za slednjo je značilen pojav ne-obstruktivne zlatenice, varikoznih 
krvavitev, pogostih okužb, hepatične encefalopatije ali pojav ascitesa. Stadiji 
napredovale kronične jetrne bolezni dobro sovpadajo z napovedjo smrtnosti 
bolnika in naj bi s tem predstavljali osnovo kliničnega ukrepanja oziroma 
potencialnega zdravljenja bolezni (5-7,10). 
 
9.2. Povzetek uvoda - nadaljevanje 
Podhranjenost je prisotna pri približno 20% bolnikov s kompenzirano (stadij 1 in 
2) in pri 60% bolnikov z dekompenzirano obliko bolezni (stadij 3-5) (6,7). 
Podhranjenost je prehransko stanje, kjer pomanjkanje ali neravnovesje energije, 
beljakovin ali drugih hranil povzroči neželene učinke na telesno ali tkivno 
gradnjo, delovanje organizma in klinični izid bolezni. Sarkopenija je definirana 
kot izguba mišične mase in zmanjšanje mišične moči in funkcije. Izguba ni 
vezana izključno na račun mišične atrofije, ampak je pri tem udeleženo tudi 
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nadomeščanje mišičja z maščobo (miosteatoza) in vezivnim tkivom (10). 
Glede na smernice se za oceno sarkopenije lahko uporabi kombinacija ocene 
mišične mase z dvojnoenergijsko rentgensko absorpcijometrijo in ocene 
mišične funkcije z meritvijo hitrosti hoje (npr. 4m test hoje). Laboratorijsko 
najpogosteje določamo vrednosti albumina, železa, cinka, prealbumina, 
transtiretina in fosfata. Omenjene preiskovalne metode so slabo uporabne in 
ponovljive na področju odkrivanja sarkopenije pri bolnikih z dekompenzirano 
jetrno cirozo zaradi pogoste sarkopenične debelosti in pojava ascitesa in 
perifernih edemov (8,10,13,14).  
Klinični podatki kažejo, da je v obratni smeri sarkopenija pomemben dejavnik 
pojava dekompenzacije jetrne ciroze, saj bolniki z bolje ohranjeno telesno 
mišično maso kažejo manjše nagnjenje za pojav navedenih dekompenzacij 
(26,31,32). Meritve ploščine mišične mase v trebuhu omogočajo posredno 
oceno volumna celotne skeletne mišične mase. Kot mesto meritve se 
najpogosteje uporablja mišica psoas oziroma izpeljani indeksi, kot metoda 
meritve pa CT/MR preiskava v sklopu diagnostike HCC (10,13,24,25,34,35). 
Obe preiskavi sta povezani s težjo dosegljivostjo, višjo ceno in z obsevanjem 
bolnika. Tandon in sodelavci so predlagali oceno sarkopenije z ultrazvočno 
meritvijo premera stegenske mišice, ultrazvočna metoda meritve mišice psoas 
pa je bila predstavljena z dvema japonskima študijama v zdravih subjektih in v 
skupini bolnikov z jetrno cirozo. Omenjene študije so pokazale dobro korelacijo 
rezultatov s CT ocenami sarkopenije vendar so bile opravljene brez primerjave 
s klinično relevantnimi posledicami stanja (38,39). Ultrazvočnih meritev ocene 
sarkopenije v evropski populaciji bolnikov z dekompenzirano jetrno cirozo še ni. 
Zaradi lažje dostopnosti in manj invazivne narave preiskave nas zanima, ali je 
možno meritev premera mišice psoas in izračun kliničnih indeksov opraviti tudi 
z ultrazvočno preiskavo. Pričakovana potrditev hipoteze bi olajšala odkrivanje 
in zgodnje zdravljenje sarkopenije pri bolnikih z dekompenzirano jetrno cirozo. 
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9.3. Materiali in metode - povzetek 
i) Opis preiskovancev 
Pri 75 zaporedno vključenih bolnikih smo za potrebe opazovalne študije med 
januarjem 2016 in novembrom 2017 opravili ultrazvočni pregled v SB Celje. 
Vključeni so bili bolniki s predhodno ali obstoječo dekompenzacijo ciroze v 
populaciji bolnikov, ki je potrebovala ultrazvočni pregled z namenom presejanja 
na pojav jetrnoceličnega karcinoma (HCC). Vključitveni dejavniki so bili: 
prisotnost ciroze glede na klinične ali radiološke znake (UZ ali CT morfološki 
znaki, elastografski znaki, laboratorijski znaki glede na CHILD lestvico) (1); 
anamneza obstoječe ali predhodne dekompenzacije s pojavom ascitesa, 
bakterijske okužbe (ki je potrebovala hospitalno zdravljenje), hepatične 
encefalopatije, varikozne krvavitve ali zlatenice znotraj enega leta pred 
vključitvijo v študijo. Prisotnost ascitesa je bila v vseh primerih potrjena 
ultrazvočno. Pojav hepatične encefalopatije ali zlatenice je bil opredeljen po 
sprejetih smernicah (40,41). Zunaj jetrna zaporna zlatenica je bila izključena z 
ultrazvočnim pregledom. Varikozna krvavitev je bila potrjena z gastroskopskim 
pregledom. Znaki okužbe so bili opredeljeni kot akutni porast vnetnih kazalcev 
v krvi (CRP, PCT) in potreba po zdravljenju z antibiotikom. Odsotnost dokaza 
povzročitelja vnetja ni bila izključitveni dejavnik. V preiskavo nismo vključili 
bolnike z znanim HCC ali drugo aktivno rakavo boleznijo. Kot kontrolno skupino 
smo vključili 20 zdravih subjektov brez znanih kroničnih bolezni notranjih 
organov in brez aktivne rakave bolezni.  
Iz računalniškega sistema smo ločeno zbrali klinične podatke - spol, starost, 
višino, težo, etiologijo kronične jetrne bolezni in pojav predhodne ali obstoječe 
dekompenzacije; in podatke laboratorijskih preiskav (hemogram, elektroliti, 
jetrna in ledvična funkcije).  
 
ii) Meritev mišice psoas 
Ultrazvočno meritev sem opravil doktorski študent, kot preiskovalec nisem bil 
seznanjen z značilnostmi preiskovanca. Bolnik je preiskavo opravil tešč 6 ur v 
položaju leže na hrbtu. Med preiskavo je bila pri vsakem vključenem subjektu 
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prepoznana mišica psoas desno in ob njej ležeče ledveno vretence. 
Abdominalna sonda je bil položena v sagitalnem preseku in v lokaciji subrenalno 
desno tik nad zgornjo mejo medenice (krista iliaka). S premikanjem sonde v 
smeri anteromedialno in posterolateralno smo zajeli največji ultrazvočno viden 
premer mišice psoas (Slika 7-11). Opravili smo trikratno meritev največjega 
premera v milimetrih (mm). Kot končni rezultat se je upoštevala srednja vrednost 
vseh treh meritev. Opredelili smo zanesljivo meritev mišice psoas, ki je morala 
izpolnjevati naslednji merili: a) jasno vidne vse omenjene anatomske meje; b) 
nobena izmed treh meritev maksimalnega premera mišice psoas ni odstopala 
od preostalih dveh za več kot 5 mm. Meritve, ki niso dosegale teh kriterijev smo 
izločili in opredelili dejavnike, ki so vplivali na nezanesljiv rezultat meritve. 
Glede na doslej predlagane kazalce mišice psoas iz študij, ki so za meritev 
uporabile CT preiskavo, smo po analogiji izračunali kazalec razmerja premera 
psoasa in telesne višine (ang. psoas-to-height-ratio; US-PTHR) kot kvocient 
med povprečno vrednostjo premera mišice psoas in bolnikovo višino (enota 
mm/m) in kazalec psoas-mišica (ang. psoas-muscle-index; US-PMI) po 
naslednji formuli: US-PMI = Π x polmer mišice psoas2/bolnikova višina2 (enota 
cm2/m2). 
 
iii) Statistična analiza 
Anonimizirane podatke vključene populacije smo uporabili za opisno statistiko 
populacije. Primerjavo med študijsko in kontrolno skupino smo opravili z 
uporabo T-testa. V študijski skupini smo opravili uni- in multivariatno obdelavo 
podatkov z uporabo Coxovega modela. Za oceno povezanosti številskih 
spremenljivk smo opravili analizo z multiplo linearno regresijo.  
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9.4.Rezultati – povzetek 
Glavne klinične značilnosti študijske in kontrolne skupine so podane v Tabeli 1 
in Tabeli 2. 
9.4.1.Uporabnost ultrazvočne meritve mišice psoas pri dekompenzirani 
cirozi 
Ultrazvočna meritev je bila opravljena uspešno in zanesljivo pri 54 (72%) od 75 
vključenih bolnikov. Med preostalimi 21 bolniki pri 7 (9,3%) meritev ni bila 
zanesljiva, pri 14 (18,7%) bolnikih pa meritev ni bila možna. Pridobitev meritve 
v kakršnikoli obliki (zanesljiva in nezanesljiva meritev) je bila izvedljiva v 
približno 80%.  
Pri zanesljivih meritvah je bila povprečna vrednost premera mišice psoas 34 
mm. Ocenjena relativna napaka ultrazvočne meritve je bila 0,08 (8%) (absolutna 
napaka meritve 3mm). Za nadaljnjo analizo smo izračunali ultrazvočna kazalca 
US-PTHR in US-SMI (Tabela 2). Povprečna vrednost US-PTHR je bila 20 mm/m, 
povprečna vrednost US-SMI je bila 3.2 cm2/m2. 
9.4.2. Uporabnost ultrazvočne meritve mišice psoas v kontrolni skupini 
Ultrazvočna meritev mišice psoas v kontrolni skupini je bila uspešna in 
zanesljiva pri 20 od 20 vključenih subjektov (100%). Vrednosti US-PTHR in US-
SMI so bile v kontrolni skupini statistično značilno višje kot v študijski skupini 
(p<0.0001 v obeh primerih, analiza prilagojena na spol in starost). 
 
9.4.3.Ultrazvočni kazalci mišice psoas in hospitalizacija zaradi nadaljnje 
dekompenzacije jetrne ciroze 
Mediana trajanja opazovanja je bila 12 mesecev. Med opazovanjem je 37 
bolnikov (68,5%) potrebovalo ponovno hospitalizacijo zaradi nadaljnje 
dekompenzacije (9 zaradi okužbe, 14 zaradi ascitesa in 8 zaradi hepatične 
encefalopatije). Tako US-PTHR kot US-SMI sta bila značilno povezana s 
tveganjem za hospitalizacijo zaradi nadaljnje dekompenzacije z razmerjem 
obetov 0.16; (95% CI 0.05-0.50; p = 0.002) v prvem in 0.58 (95% CI 0.42-0.81; 
p=0.002) v drugem primeru. Z multivariatno analizo prilagojeno glede na MELD, 
CHILD in prisotnost varic zgornjih prebavil smo potrdili neodvisno povezanost 
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tako US-PTHR kot US-SMI s hospitalizacijo zaradi nadaljnje dekompenzacije 
jetrne ciroze (p<0.0001 v obeh primerih).  
9.4.4.Ultrazvočni kazalci mišice psoas in smrtnost pri dekompenzirani 
jetrni cirozi 
Med opazovanjem študijske skupine je umrlo 15 (27.8%) bolnikov. Srednji čas 
preživetja je bil 8,0 mesecev, povprečni omejeni čas preživetja pa 11.7 mesecev. 
Vzrok smrti je bil povezan z jetrno cirozo v 12 primerih (bakterijska okužba pri 
petih, HCC pri šestih in varikozna krvavitev pri enem bolniku). Z multivariatno 
analizo prilagojeno glede na MELD seštevek je bila vrednost US-PTHR značilno 
povezana s smrtnostjo (p=0.022; HR 0.825, 95% CI 0.701-0.973), prav tako 
vrednost US-SMI (p=0.017; HR 0.930, 95% CI 0.876-0.987). 
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9.5. Razprava – povzetek  
Glavna ugotovitev retrospektivne analize prospektivno zbranih podatkov v enem 
sekundarnem bolnišničnem centru je, da je ultrazvočna meritev premera mišice 
psoas in iz nje izpeljani kazalci uporabna pri bolnikih z dekompenzirano jetrno 
cirozo, in kaže klinično uporaben pomen, saj je značilno povezana z obeti za 
nadaljnjo dekompenzacijo bolezni, ki potrebuje hospitalizacijo. Naslednji 
rezultat naše študije je, da ultrazvočno ocenjeni kazalci mišice psoas neodvisno 
napovedujejo smrtnost pri bolnikih z dekompenzirano jetrno cirozo. Na tem 
področju bi imele ultrazvočne preiskovalne metode tako pomembno prednost, 
saj gre za obposteljno metodo, kar bi olajšalo klinično stratifikacijo bolnikov z 
dekompenzirano boleznijo v pripravi na presaditev jeter. Čeprav z našo študijo 
nismo predlagali mejnih vrednosti ultrazvočnih kazalcev, pa lahko predstavlja 
osnovo za dodatno študijo, ki bi definirala te vrednosti. 
Omejitve naše študije so retrospektivna in monocentrična analizo podatkov, ki 
vključuje relativno majhno število bolnikov. Ultrazvočno preiskavo je opravil en 
sam preiskovalec, prav tako naša študija ne podaja primerjave s CT preiskavo, 
ki je predlagana kot standardna preiskovalna metoda (10). V študiji nismo vzeli 
v obzir številnih drugih dejavnikov, ki pomembno vplivajo na klinični izhod 
bolnikov z dekompenzacijo jetrne ciroze (npr. vpliv mišične funkcije, vpliv 
maščobnega in vezivnega preustroja skeletne mišice).  
Kljub navedenim omejitvam rezultati naše študije poudarjajo uporabnost in 
izvedljivost preproste, dostopne, objektivne, ponovljive in ob posteljne metode 
za meritev premera mišice psoas kot pokazatelja sarkopenije pri bolnikih z 
dekompenzirano jetrno cirozo. Ultrazvočna meritev mišice psoas je imela v naši 
populaciji prognostično vrednost glede nadaljnje dekompenzacije in smrtnosti in 
s tem študijsko nakazan vpliv na razvrščanje bolnikov na listo za presaditev jeter. 
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9.6 Zaključek 
Ultrazvočna meritev premera mišice psoas je izvedljiva v populaciji bolnikov z 
dekompenzirano jetrno cirozo. 
Premer mišice psoas izmerjen s predlagano ultrazvočno metodo v naši študiji je 
značilno različen (manjši) ob primerjavi mediane skupine bolnikov z jetrno cirozo 
in skupine zdravih prostovoljcev. 
Izračunana ultrazvočna kazalca (US-PTHR, US-PMI) kažeta primerne lastnosti 
za posredno oceno tveganja za razvoj nadaljnje dekompenzacije jetrne ciroze 
in oceno tveganja za pojav smrtnosti. 
Ultrazvočna metoda ocene sarkopenije s pomočjo meritve premera mišice 
psoas in izračunanih kazalcev US-PTHR/US-PMI lahko predstavlja uporaben 
kliničen pripomoček za prepoznavanje in spremljanje sarkopenije pri bolniku z 
jetrno cirozo. 
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